Lilly to present new Alzheimer’s drug data at AAIC 2014

Lilly has announced that it will be attending and sharing clinical data at the 2014 Alzheimer's Association International Conference (AAIC), which takes place in Denmark next week.

The event will run from July 12th to 17th in Copenhagen, with Lilly to give 23 presentations on its latest dementia research and drug development efforts relevant to this important area.

Three oral presentations will examine a number of important topics, such as the use of combination therapy to achieve maximal removal of beta-amyloid pathology, the relationship between cognitive and functional decline in mild Alzheimer's disease, and the effect of amyloid imaging on the diagnosis and management of patients with cognitive decline.

Lilly will also present additional analyses from phase III and ongoing open-label studies of several key drugs, including solanezumab.

Dr Eric Siemers, senior medical director of Lilly's Alzheimer's disease team, said: "The coming together of the scientific community at this meeting is crucial as the prevalence of the disease continues to rise, with over 44 million people around the world with dementia."

The company markets a number of products for use in the treatment and diagnosis of Alzheimer's, including Amyvid, a radioactive diagnostic agent that was launched last year.